Baltimore, MD – A large U.S. registry study has found that people living with Cystic fibrosis who are treated with CFTR modulator therapies experience a significantly lower risk of death compared with untreated patients, with an overall reduction of 66% over an eight-year follow-up period. The findings, published in CHEST,...

South Bend, Indiana – A groundbreaking neurobiology study has delivered the first direct scientific comparison of the two dominant laboratory models used to study multiple sclerosis (MS), potentially reshaping how future treatments are developed. Published by researchers at University of Notre Dame, the study examined how two widely used experimental...

Barcelona, Spain – Alterations in the TP53 gene represent an intrinsic biomarker of very poor outcomes in pediatric and young adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL) treated with the anti-CD19 CAR-T therapy tisagenlecleucel (tisa-cel). This was discovered by a group of Spanish researchers, who recently...